GlassScriptPhysician profile
Avi Landman
NPI 1174082002
$36,200.19
in general payments reported to CMS, 2019-2025
22 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.38 · 2023: $118 · 2024: $250 · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $4,688 · Travel and Lodging: $3,264 · Food and Beverage: $3,223 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,887.50 |
| Consulting Fee | $4,687.50 |
| Travel and Lodging | $3,263.59 |
| Food and Beverage | $3,223.26 |
| Education | $106.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30,896.19 | 2024-2025 | Uplizna |
| Grifols Shared Services North America, INC. | $3,066.01 | 2025 | Gamunex-C |
| Janssen Scientific Affairs, LLC | $504.09 | 2024-2025 | |
| Abbvie INC. | $338.16 | 2023-2025 | |
| Averitas Pharma INC. | $245.73 | 2025 | Qutenza |
| Argenx US, INC. | $237.19 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Janssen Biotech, INC. | $175.49 | 2025 | |
| Ucb, INC. | $152.11 | 2025 | Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $79.96 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $77.07 | 2025 | Hyqvia |
| Genentech USA, INC. | $75.04 | 2025 | Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $57.30 | 2024 | Nuplazid |
| Itf Therapeutics LLC | $56.76 | 2025 | |
| Tanabe Pharma America, INC. | $41.48 | 2025 | Radicava |
| Alnylam Pharmaceuticals INC. | $34.02 | 2025 | Onpattro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microtransponder, INC. | $32.29 | 2025 | |
| Eisai INC. | $27.61 | 2025 | |
| Livanova USA, INC. | $25.24 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $24.93 | 2025 | |
| Merz Pharmaceuticals, LLC | $22.14 | 2024 | Xeomin |
| E.R. Squibb & Sons, L.L.C. | $18.95 | 2020 | |
| Adamas Pharmaceuticals, INC. | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Landman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.